Physician profile
Michael L Blake
NPI 1417111493
$5,948.05
in general payments reported to CMS, 2019-2025
23 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $633 · 2021: $1,285 · 2022: $591 · 2023: $137 · 2024: $1,033 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,326.20 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $1,317.37 | 2019-2024 | Xarelto |
| Abbvie INC. | $750.10 | 2021-2025 | Teflaro, Avycaz |
| Novartis Pharmaceuticals Corporation | $434.01 | 2019-2023 | |
| Glaxosmithkline, LLC. | $292.59 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.71 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Allergan, INC. | $243.81 | 2019-2020 | |
| Novo Nordisk INC | $211.79 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.40 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $143.52 | 2024-2025 | Cologuard Collection Kit |
| Neurelis, INC. | $125.00 | 2021 | |
| Pfizer INC. | $119.65 | 2023-2025 | |
| Lilly USA, LLC | $114.71 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $102.28 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $95.09 | 2024-2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $66.17 | 2024-2025 | Trintellix |
| Daiichi Sankyo INC. | $31.23 | 2024-2025 | Injectafer |
| Philips North America LLC | $19.30 | 2020 | |
| Sumitomo Pharma America, INC. | $17.06 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $17.02 | 2025 | Gardasil 9, Capvaxive |
| Mylan Specialty L.P. | $14.61 | 2021 | |
| Melinta Therapeutics, LLC | $14.26 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.